Business Context and Reporting Period
This Form 8-K, dated December 31, 2006, reports the completion of a reverse merger between Orthodontix, Inc. (a Florida shell company) and Protalix Ltd., an Israeli biotechnology company. Following the merger, Protalix Ltd. became the sole operating subsidiary, and the registrant intends to change its name to Protalix BioTherapeutics, Inc. The company operates a proprietary plant cell expression system to produce recombinant therapeutic proteins. Its lead product candidate, prGCD, is a treatment for Gaucher Disease, which has completed Phase I clinical trials and is preparing for a pivotal Phase III trial expected to commence in 2007.
Key Financial Metrics
Revenue: The company has generated no product sales revenue. Historical revenue was minimal, derived solely from research and development milestone payments (e.g., $150,000 in 2005). No revenue was recorded for the nine months ended September 30, 2006.
Profitability: The company is not profitable and has an accumulated deficit of approximately $17.0 million as of September 30, 2006. Net losses for the nine months ended September 30, 2006, were approximately $5.9 million.
Cash Flow and Liquidity: As of September 30, 2006, Protalix Ltd. held cash and cash equivalents of $15.6 million. In connection with the merger, an additional $8.7 million was received from the exercise of outstanding warrants. Management believes these funds are sufficient to meet operating needs for at least the next twelve months.
Debt: The company had no long-term debt as of September 30, 2006, having repaid a $1.0 million loan in December 2005.
Capital Structure: The merger resulted in the issuance of approximately 61.2 million shares of common stock to former Protalix shareholders, representing over 99% of the outstanding shares. A one-for-ten reverse stock split was effected.
Material Changes
- Corporate Structure: Orthodontix, Inc. ceased its previous orthodontic practice management operations and adopted the biopharmaceutical business of Protalix Ltd. via a reverse merger.
- Ownership: Former Protalix shareholders now control the company. Significant investors include a trust controlled by Dr. Phillip Frost, who received approximately 15.8% of the outstanding shares.
- Stock Symbol: The trading symbol was changed from "OTIX.BB" to "ORTX.BB" (with an intent to change to "PLXB" upon listing on the American Stock Exchange).
- Financial Position: The pro forma balance sheet reflects a significant increase in cash assets due to the merger and warrant exercises, offset by a large accumulated deficit.
Guidance, Outlook, and Risks
Outlook: The company expects to incur substantial losses for the foreseeable future as it advances prGCD into Phase III trials and develops its pipeline (including PRX-102 for Fabry disease and PRX-111 for infertility). It anticipates spending a minimum of $5 million on clinical development over the next twelve months.
Management Commentary: Management highlights the cost-effectiveness and safety advantages of its plant cell expression system compared to traditional mammalian cell systems. They have entered into a collaboration with Teva Pharmaceutical Industries Ltd. for the development of two proteins.
Risks and Contingencies:
- Regulatory Approval: There is no assurance that the FDA will approve the initiation of Phase III trials or grant marketing approval for any product candidates.
- Liquidity: The company will require additional financing to fund operations beyond the next twelve months. Failure to secure funding could force a reduction in development activities.
- Israeli Operations: Operations are concentrated in Israel, exposing the company to political, economic, and military instability. Additionally, government grants received are subject to strict conditions regarding manufacturing location and technology transfer.
- Intellectual Property: The company relies on patents and licenses; infringement claims or failure to secure necessary licenses could hinder commercialization.
Investor Verification Checklist
- Verify the status of the FDA application for the Phase III clinical trial of prGCD and the timeline for its commencement.
- Confirm the sufficiency of the $24.7 million pro forma cash balance against the projected $5 million+ burn rate for the upcoming year.
- Review the terms of the collaboration agreement with Teva Pharmaceutical Industries Ltd. and the potential for milestone payments.
- Assess the impact of Israeli tax rulings and government grant restrictions on future manufacturing and technology transfer capabilities.
- Monitor the company's progress in listing on the American Stock Exchange and the associated lock-up agreements for major shareholders.